ClinicalTrials.gg
RecruitingNCT07764497HAIP-6192Updated Aug 14, 2026

Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis

A Phase 2 interventional study of Floxuridine (FUDR) in Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer and Liver Metastases From Colorectal Cancer, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 11 months after the study started (first participant enrolled Jul 2014, registered Jun 2026).
  • Started Jul 2014; still recruiting 12 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing floxuridine in Colonic Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Floxuridine · Colonic Neoplasms.

Planned enrollment
Largest of 15
200 · median 49
Started
2014
the only one that year
Phase 2
11 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies testing floxuridine in Colonic Neoplasms, this one has the largest planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2014, is one of 11 in phase 2, and was the 18th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

1 of the 18 studies testing floxuridine in Colonic Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About floxuridine

Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing floxuridine in Colonic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care systemic chemotherapy.

03

Conditions studied

  • Colorectal Adenocarcinoma Metastatic in the Liver
  • Liver Metastasis Colon Cancer
  • Liver Metastases From Colorectal Cancer
  • Liver Metastases of Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of confirmed colorectal adenocarcinoma to the liver with no clinical or radiographic evidence of extrahepatic disease. Patients with resectable or ablatable lung metastasis are eligible.
  2. Physically able to tolerate major partial hepatectomy.
  3. The primary tumor may be in place at the time of registration if not obstructing the intestinal lumen or significantly bleeding. If present, the primary tumor will be resected at the time of pump placement.
  4. Chest, Abdominal and Pelvic CT scan with CT angiogram within 6 weeks prior to registration. (MRI angiogram with contrast of the abdomen may be substituted for CT of the abdomen).
  5. The patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. In the event that two hepatobiliary surgeons cannot agree, a third surgeon will be consulted. Continued discrepancy will result in the patient's case being presented at weekly hepatobiliary conference for consensus opinion. Inoperable metastases are defined as: requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial/portal inflow, venous outflow and biliary drainage. * A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.
  6. Patient's liver metastases must comprise \<70% of the liver parenchyma.
  7. Female patients of child-bearing age must undergo a pregnancy test and have a negative result.
  8. A patient must have had prior chemotherapy.
  9. PS \< 2.
  10. Within 14 days of registration: o WBC >3X10E9/L; ≥ 1.5X10E9/L; count >100X10E9/L; \< 1.5; HGB ≥ 90 g/L; Estimated ≥30 ml/min (using Cockcroft and Gault formula); Total serum \<25.6 umol/L.
  11. Age ≥ 18 years.
  12. Signed .
  13. Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  14. Patients with limited/responding lung metastases on Physician's discretion.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration).
  2. Patient may not have received prior treatment with FUDR.
  3. Active infection, ascites, hepatic encephalopathy.
  4. Active concurrent , except a patient's potentially resectable colorectal primary.
  5. Extrahepatic except for resectable or ablatable lung metastasis.
  6. Patient must not have obstruction of GI or GU tract.
  7. Female patients who are pregnant or lactating.
  8. Patients may not be receiving any other agents.
  9. Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded (history of stroke or within 6 months prior to Day 1).
  10. Serious or non-healing active wound, ulcer, or bone fracture.
  11. Chronic daily treatment with aspirin (> 325 mg/d) or nonsteroidal anti- inflammatory medications known to inhibit the function.
  12. Presence of bleeding diathesis or coagulopathy.
  13. History of serious systemic disease, including myocardial infarction within the last 6 months, uncontrolled hypertension (blood pressure of > 150/100 mmHg on medication), unstable angina, (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Hepatic arterial infusion pump therapy

    Hepatic arterial infusion pump therapy with floxuridine (FUDR) and dexamethasone will be administered on Day 1 of each cycle. The pump will be emptied and filled with normal saline on Day 15. Standard of care systemic chemotherapy will be administered on Day 1 and Day 15 as per the treating medical oncologist.

    Drug: Floxuridine (FUDR)

Interventions

  • Floxuridine will be administered at a recommended dose of 0.12 mg/kg/day and adjusted as per participants weight and lab results.

06

What researchers measure

Primary outcomes

  1. Proportion of participants that undergo liver resection following treatment with FUDR

    To assess the rate of conversion to liver resection in patients with initially inoperable hepatic-metastases due to colorectal cancer after treatment with hepatic artery infusion pump therapy and standard of care systemic therapy.

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

Secondary outcomes

  1. Time to disease progression in all participants

    To evaluate time to progression (TTP).

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

  2. Time prior to disease progression in all participants

    To evaluate disease-free survival (DFS).

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

  3. Time to intrahepatic disease progression in all participants

    To evaluate time to disease progression in liver.

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

  4. Time to death in all participants

    Overall survival

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

  5. Number of participants with complete response, partial response, progressive disease, or stable disease as per RECIST Version 1.1

    To determine the response rate to systemic chemotherapy and FUDR.

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.

  6. Number of participants with grade 3 or higher adverse events as per CTCAE Version 4.03

    To evaluate the safety and tolerability of hepatic arterial infusion pump therapy and standard of care systemic therapy.

    Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — To be determined on a case by case basis and appropriate participant consent, research ethics board review, and execution of legal agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2014 (actual). Primary completion is estimated for Dec 2036, 269 months after the start.

Of 123 non-industry phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 269 months is above that.

Counting every sponsor, half of 136 studies reached it within 43 months; a quarter within 30 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Aug 14, 2026
StartActual
Jul 2014
Primary completionEst.
Dec 2036
CompletionEst.
Dec 2036
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764497
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Jul 2014
Primary completion
Dec 2036 (estimated)
Completion
Dec 2036 (estimated)
Last update
Aug 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Floxuridine

Start the discussion